# Bone Biologics Corporation (BBLG) · Edgar & Edgarette company card

> Bone Biologics (BBLG) grew revenue 0.0% in FY2020 to $1.1 billion, operating margin -0.1% against a 11.0% median for orthopedic, prosthetic & surgical appliances & supplies. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1419554 · fiscal year ended 2020-12-31 · 2 audited years read · [page](https://www.pops4.com/boards/company/BBLG) · [JSON](https://www.pops4.com/boards/company/BBLG.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $1.1B |
| Revenue growth, 1 year | 0.0% |
| Revenue growth per year | — |
| Operating margin | -0.1% (prior year -0.2%) |
| Net margin | -0.2% |
| Operating cash flow | −$426,933 |
| Capital spending | — |
| Free cash flow | — |
| Cash | — |
| Long-term debt | — |
| Total assets | $0 |
| Total equity | −$14M |
| Equity ÷ assets | — |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Health Harbor boat: Sound ship · one warning sign · operating cash flow was negative (-$2.7M in FY2025)

## Edgarette's reading

Exposure: revenue $1.1B (FY2020). Experience: revenue up 0.0% on the year; operating margin -0.1%, up from -0.2%. Credibility: 2 audited years, moderate weight. Range: 80% of past cases like this landed between $851.0M and $1.3B next year (method v3, set from 4,599 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (13 filers, $50M+ revenue, orthopedic, prosthetic & surgical appliances & supplies): operating margin -0.1% against a 11.0% median; growth 0.0% against 7.5%.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 1, latest 2026-09-16 ([filing](https://www.sec.gov/Archives/edgar/data/1419554/000149315226042940/0001493152-26-042940-index.htm))

## Recent filings

- 10-Q · filed 2026-10-26 · [filing](https://www.sec.gov/Archives/edgar/data/1419554/000149315226048571/0001493152-26-048571-index.htm)
- 8-K · filed 2026-09-29 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1419554/000149315226044889/0001493152-26-044889-index.htm)
- 8-K · filed 2026-09-16 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule · [filing](https://www.sec.gov/Archives/edgar/data/1419554/000149315226042940/0001493152-26-042940-index.htm)
- DEF 14A · filed 2026-08-28 · [filing](https://www.sec.gov/Archives/edgar/data/1419554/000149315226040640/0001493152-26-040640-index.htm)
- 10-Q · filed 2026-08-14 · [filing](https://www.sec.gov/Archives/edgar/data/1419554/000149315226038482/0001493152-26-038482-index.htm)
- 8-K · filed 2026-07-23 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1419554/000149315226034334/0001493152-26-034334-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001419554.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1419554

## Cite

POPS4, Edgar & Edgarette: Bone Biologics Corporation (BBLG) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/BBLG. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Its latest audited year is FY2025, which reports no revenue; the revenue figures and the range here are from FY2020, its last year with revenue on record. Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.